Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 10Uterine Cervical Neoplasms 9Lung Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Urinary Bladder Neoplasms 5Stomach Neoplasms 5Small Cell Lung Carcinoma 4Mesothelioma, Malignant 4Medulloblastoma 4Urethral Neoplasms 3Oropharyngeal Neoplasms 3Neuroblastoma 3Head and Neck Neoplasms 3Ganglioneuroblastoma 3Cholangiocarcinoma 3Vulvar Neoplasms 2Vaginal Neoplasms 2Ureteral Neoplasms 2Tongue Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Lymphoid Interstitial Pneumonia 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Brenner Tumor 2Brain Neoplasms 2Vomiting 1

Interventions

berzosertib 1Platinum 1Gemcitabine 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Metastatic Bladder Urothelial Carcinoma × Platinum × Clear all
NCT02567409 2025-03-03

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
87 enrolled 13 charts
Genitourinary

Metastatic Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡